(Available Soon)
CSE: BUX | OTCQB: BMKDF
BIOMARK_DIAGNOSTICS_INC_EXPANDS_PHASE_3_CLINICAL_TRIALS (PDF)
————————————————-
BioMark Diagnostics Inc. announces its upcoming participation in two premier Canadian life sciences events: MSACL 2026 and BIOHorizon 2026 . The company will present advances in its metabolomics-based liquid biopsy
BioMark Diagnostics reports five peer-reviewed publications in nine months validating its metabolomics liquid biopsy for early NSCLC detection. New studies show high accuracy (up to 96.9% ROC-AUC), compact AI/ML panels,
BioMark Diagnostics endorses the 2026 World Lung Cancer Day global call for equitable access to early screening. The company advances its metabolomics-based liquid biopsy platform, validated in Quebec and the
BioMark Diagnostics receives formal patent allowances from CIPO (Canada) and the EPO (Europe) for its early-stage lung cancer blood test. The metabolomics platform and algorithm are validated across more than